Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$452.0K-86.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric K. Olson
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 32
- Beta
- 0.64
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -41.40
Financials
Revenue
$452.0K-86.6%Net Income
$-2.71MEBITDA
$-2.63MFree Cash Flow
$-2.85MEPS (diluted)
$-0.75Shares Outstanding (diluted)
4.85M+661505.7%Operating Expenses
$3.16MCash & Debt
$3.59MReturn of Capital
$0.00Revenue by Segment (annual)
$1.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.02M | $-17.08M | $-6.16 |
| 2024 | $1.25M | $-11.02M | $-14.87 |
| 2023 | $2.63M | $-8.26M | $-35.43 |
| 2022 | $601.0K | $-12.04M | $-54.67 |
| 2021 | $606.0K | $-9.31M | $-47.59 |
| 2020 | $594.0K | $-7.03M | $-44.57 |
| 2019 | $689.0K | $-4.80M | $-311.65 |
| 2018 | $95.0K | $-8.65M | $-2373.00 |
| 2017 | $11.23M | $-9.33M | $-9395.07 |
| 2016 | $15.23M | $-16.60M | $-32255.41 |
| 2015 | $19.45M | $-23.91M | $-106750.00 |
| 2014 | $22.77M | $-32.58M | $-678791.67 |
| 2013 | $22.31M | $-8.29M | $-376636.36 |
| 2012 | $23.07M | $-35.03M | $-1592484.95 |
Valuation
SINThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90-10.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·5d ago·Negative
SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone also enables Company to call Class B warrants SALT LAKE CITY, Utah, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics…
View source ↗ - Newsglobenewswire.com·22d ago·Negative
SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts Experts in implant retrieval, biomaterials and clinical practice examine the science, clinical experience and potential advantages of silicon nitride relative to established implant materials in Company-sponsored Orthopedics This Week Masterclass SALT LAKE CITY, Utah, Sept. 14, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials …
View source ↗ - Newszacks.com·47d ago·Positive
SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·55d ago·Neutral
Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.34 per share
Typical surprise -6.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.75 vs $-0.73miss
- Fri, May 15$-0.70 vs $-0.66miss
- Wed, Mar 18$-0.56 vs $-0.55miss
- Wed, Nov 12$-3.46 vs $-0.55miss
- Thu, Aug 14$-0.91 vs $-0.79miss
- Thu, May 15$-1.29 vs $-0.76miss
Estimates and results for SINT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SINT officers and directors.
- Bought
- $729k
- Sold
- $3k
52 trades
2 trades
- Lyons Christopher Michaelbought
- Lyons Christopher Michaelbought
- Moyes Jay Mbought
- Anderson Mark Lewisbought
- Honigblum Gregg R.bought
- Honigblum Gregg R.bought
- Honigblum Gregg R.bought
- Honigblum Gregg R.bought
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SINT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.